

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Biocon Pharma Limited
Petitioner,

v.

Novartis Pharmaceuticals Corporation
Patent Owner.

U.S. Patent No. 8,101,659 to Ksander *et al.*

Issue Date: January 24, 2012

Title: Methods of Treatment and Pharmaceutical Composition

Inter Partes Review No.: IPR2020-01263

**PETITIONER'S CORRECTED EXHIBIT
LIST AS OF AUGUST 10, 2020**

Exhibit #	Description
1001	U.S. Patent No. 8,101,659 (“the ’659 patent”)
1002	EP Patent Application No. 0726072A2 (“EP’072”)
1003	Trippodo <i>et al.</i> , “REPRESSION OF ANGIOTENSIN II AND POTENTIATION OF BRADYKININ CONTRIBUTE TO THE SYNERGISTIC EFFECTS OF DUAL METALLOPROTEASE INHIBITION IN HEART FAILURE”, <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 272, No. 2, February 01, 1995, 619-627 (“Trippodo”)
1004	Shetty <i>et al.</i> , “DIFFERENTIAL INHIBITION OF THE PREJUNCTIONAL ACTIONS OF ANGIOTENSIN II IN RAT ATRIA BY VALSARTAN, IRBESARTAN, EPROSARTAN, AND LOSARTAN”, <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 294, No. 1, July 01, 2000, 179-186 (“Shetty”)
1005	Gomez-Monterrey <i>et al.</i> , “NEW THIOL INHIBITORS OF NEUTRAL ENDOPEPTIDASE EC 3.4.24.11: SYNTHESIS AND ENZYME ACTIVE-SITE RECOGNITION”, <i>Journal of Medicinal Chemistry</i> , Vol. 37, Issue 12, June 01, 1994, 1865–1873. (“Gomez-Monterrey”)
1006	Ksander <i>et al.</i> , “DICARBOXYLIC ACID DIPEPTIDE NEUTRAL ENDOPEPTIDASE INHIBITORS”, <i>Journal of Medicinal Chemistry</i> , Vol. 38, Issue 10, May 01, 1995, 1689–1700 (“Ksander”)
1007	Reserved
1008	U.S. Patent No. 5,399,578 (“the ’578 patent”)
1009	U.S. Patent No. 5,217,996 (“the ’996 patent”)
1010	The prosecution history for U.S. Patent No. 8,101,659 (“the ’659 prosecution history”)

Exhibit #	Description
1011	Thurmann, "VALSARTAN: A NOVEL ANGIOTENSIN TYPE 1 RECEPTOR ANTAGONIST," Expert Opinion on Pharmacotherapy, Vol. 1, Issue 2, January 2000, 337-350 ("Thurmann")
1012	Physician's Desk Reference (2000), DIOVAN® ("PDR")
1013	Roques, <i>et al.</i> , "NEUTRAL ENDOPEPTIDASE 24.11: STRUCTURE, INHIBITION, AND EXPERIMENTAL AND CLINICAL PHARMACOLOGY," Pharmacological Reviews, Vol. 45, Issue 1, March 01 1993, 87-146.
1014	U.S. Patent No. 7,468,390 ("the '390 patent")
1015	The prosecution history for U.S. Patent No. 7,468,390 ("the '390 prosecution history")
1016	Ferrario, <i>et al.</i> , "COUNTERREGULATORY ACTIONS OF ANGIOTENSIN," Hypertension, Vol. 30, Issue 3, September 1997, 535-541 ("Ferrario")
1017	Orange Book Entry for ENTRESTO® ("Orange Book listing for ENTRESTO")
1018	Declaration and Curriculum Vitae of Prof. Y.W. Francis Lam
1019	Physician's Desk Reference (2000), NORVASC® ("PDR-NORVASC")
1020	Physician's Desk Reference (2000), TENORMIN® ("PDR-TENORMIN")
1021	Physician's Desk Reference (2000), TAGAMET® ("PDR-TAGAMET")
1022	Physician's Desk Reference (2000), LANOXIN® ("PDR-LANOXIN")
1023	Physician's Desk Reference (2000), Furosemide ("PDR-Furosemide")
1024	Physician's Desk Reference (2000), MICRONASE® ("PDR-MICRONASE")

Exhibit #	Description
1025	Physician's Desk Reference (2000), HydroDIURIL® (“PDR-HydroDIURIL”)
1026	Physician's Desk Reference (2000), INDOCIN® (“PDR-INDOCIN”)

CERTIFICATION OF SERVICE ON PATENT OWNER

Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4), and 42.105, the undersigned certifies that on August 10, 2020, a complete copy of the Updated Exhibit List, and all supporting exhibits were served via Express Mail to the Patent Owner by serving the correspondence address of record for the '659 patent:

Nicholas N. Kallas
Christina Schwarz
Jared L. Stringham
Christopher E. Loh
VENABLE LLP
1290 Avenue of the Americas
New York, New York 10104
(212) 218-2100
nkallas@venable.com
cschwarz@venable.com
jlstringham@venable.com
cloh@venable.com

David Kurlandsky
Joseph T. Majka
Novartis Pharmaceuticals Corporation
Intellectual Property Department
One Health Plaza 433/2
East Hanover, NJ
07936-1080

Respectfully submitted,
Katten Muchin Rosenman LLP

By: /Christopher B. Ferenc/
Christopher B. Ferenc
Reg. No. 59,365